UK Markets close in 3 hrs 48 mins
  • FTSE 100

    7,559.80
    +50.65 (+0.67%)
     
  • FTSE 250

    20,407.57
    +24.81 (+0.12%)
     
  • AIM

    933.11
    -1.00 (-0.11%)
     
  • GBP/EUR

    1.1866
    +0.0007 (+0.06%)
     
  • GBP/USD

    1.2016
    -0.0042 (-0.3497%)
     
  • BTC-GBP

    20,010.17
    -164.48 (-0.82%)
     
  • CMC Crypto 200

    572.83
    -17.93 (-3.04%)
     
  • S&P 500

    4,297.14
    +16.99 (+0.40%)
     
  • DOW

    33,912.44
    +151.39 (+0.45%)
     
  • CRUDE OIL

    90.16
    +0.75 (+0.84%)
     
  • GOLD FUTURES

    1,791.60
    -6.50 (-0.36%)
     
  • NIKKEI 225

    28,868.91
    -2.87 (-0.01%)
     
  • HANG SENG

    19,830.52
    -210.34 (-1.05%)
     
  • DAX

    13,905.15
    +88.54 (+0.64%)
     
  • CAC 40

    6,598.74
    +28.79 (+0.44%)
     

Is Johnson & Johnson Now a Has-Been in the COVID Vaccine Market?

·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Johnson & Johnson (NYSE: JNJ) was once viewed as a leader in the COVID-19 vaccine arena. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J is now a has-been in the COVID-19 vaccine market. Keith Speights: Reuters recently reported about another company, Johnson & Johnson.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting